Compare · GRCE vs NVO
GRCE vs NVO
Side-by-side comparison of Grace Therapeutics Inc. (GRCE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRCE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 4233.6x GRCE ($41.0M).
- GRCE has been more active in the news (10 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for GRCE).
- Company
- Grace Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $41.0M
- $173.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 10
- 4
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GRCE
- SEC Form 4 filed by Grace Therapeutics Inc.
- SEC Form 4 filed by Grace Therapeutics Inc.
- SEC Form 4 filed by Grace Therapeutics Inc.
- Large owner Opaleye Management Inc. bought $16,404 worth of shares (7,849 units at $2.09) (SEC Form 4)
- Amendment: Large owner Opaleye Management Inc. bought $31,687 worth of shares (15,089 units at $2.10) (SEC Form 4)
- Large owner Opaleye Management Inc. bought $31,687 worth of shares (15,089 units at $2.10) (SEC Form 4)
- SEC Form 4 filed by Director Davis A Brian
- SEC Form 4 filed by Director Neugeboren Edward
- SEC Form 4 filed by Director Kavuru Vimal
- SEC Form 4 filed by Director Kottayil George
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank